Abigail Alliance for Better Access to Developmental Drugs

The Abigail Alliance for Better Access to Developmental Drugs is a United States patient-advocacy organization focused on access to investigational medicines for people with terminal or otherwise life-threatening illnesses. The group was established in November 2001 by Frank Burroughs in memory of his daughter, Abigail, and became associated with a broader debate over whether patients who have exhausted approved treatment options should be able to obtain promising drugs before regulatory approval. The Alliance's central position has been that seriously ill patients, in consultation with their physicians, should have a greater ability to seek potentially beneficial developmental drugs. Its advocacy has challenged a regulatory model in which access to an unapproved medicine generally depends on a clinical-trial pathway or an expanded-access request involving the treating physician, the drug developer, and the U.S. Food and Drug Administration. The organization has argued that terminally ill patients should not be denied potentially useful treatments solely because those treatments have not yet completed the approval process. The Abigail Alliance is best known for Abigail Alliance v. von Eschenbach, a constitutional litigation campaign conducted with representation from the Washington Legal Foundation. The case sought recognition of a legal right for terminally ill patients to obtain certain investigational drugs. In August 2007, the United States Court of Appeals for the District of Columbia Circuit ruled against the Alliance in an 8–2 decision, reversing an earlier decision that had favored the organization. The Supreme Court of the United States declined to hear the appeal in 2008. The resulting legal position left no constitutional right for terminally ill patients to demand access to unapproved drugs that might be toxic and had no proven therapeutic benefit. Although the litigation did not establish the right sought by the Alliance, it gave the organization a prominent role in public discussions about compassionate use, expanded access, right-to-try laws, informed consent, regulatory risk, and the balance between individual treatment choices and the evidentiary requirements of drug approval. The Alliance's work sits within a wider movement that includes patients, families, physicians, bioethicists, pharmaceutical companies, and policymakers. The organization is an advocacy body rather than a pharmaceutical manufacturer, healthcare provider, or drug-distribution business. Its principal offering is public-policy advocacy and related representation concerning developmental drugs. The available reference material does not establish a current headquarters, operating staff, formal corporate parent, website, financial profile, or present operational status. Accordingly, those details are left unspecified.

The Abigail Alliance emerged from the United States debate over compassionate use and expanded access to investigational medicines. In the U.S. regulatory system, an unapproved drug may sometimes be provided outside a clinical trial through an expanded-access mechanism, but the process generally requires participation by the patient and physician, regulatory authorization, and cooperation from the company developing the product. A manufacturer cannot ordinarily be compelled to supply a developmental drug, and access may also depend on clinical suitability and the ability to meet associated costs. The Alliance was founded in November 2001 by Frank Burroughs in memory of his daughter, Abigail. Its advocacy sought to broaden availability of developmental drugs for people with terminal illnesses, particularly patients who lacked satisfactory approved therapies. The organization argued that patients facing imminent death should have greater autonomy to try investigational treatments after consultation with their physicians, even before the treatments had completed the evidence-gathering process required for marketing approval. The Alliance's most important public activity was its constitutional lawsuit, Abigail Alliance v. von Eschenbach. Working with the Washington Legal Foundation, the group attempted to establish that terminally ill patients possess a legal right to obtain certain investigational drugs. The litigation focused on the conflict between individual access claims and the Food and Drug Administration's role in evaluating safety and effectiveness before commercial marketing. It also raised questions about whether the Constitution protects a patient's choice to assume the risks of an unapproved medicine. On August 7, 2007, the U.S. Court of Appeals for the District of Columbia Circuit ruled 8–2 against the Alliance, reversing an earlier decision that had been favorable to it. The appellate decision rejected the proposed constitutional entitlement to obtain a potentially toxic drug lacking proven therapeutic benefit. In 2008, the Supreme Court declined to hear the appeal. The result left the Alliance without the legal precedent it sought, while maintaining the existing framework in which expanded access depends on regulatory requirements, physician involvement, and the willingness of the product sponsor. The case became a frequently cited episode in the history of U.S. expanded-access policy. It helped frame later arguments about compassionate use, patient autonomy, right-to-try laws, and the role of the FDA. The broader policy environment subsequently included state right-to-try statutes, although legal and bioethics scholars have questioned their practical significance because expanded-access pathways already existed and manufacturers remained the principal gatekeepers in many cases. The Alliance should therefore be understood primarily as an advocacy and policy organization, not as a drug company or a provider of medicines. The supplied reference material does not document a current leadership roster beyond its founder, a current website, headquarters, financial information, or a definitive active/defunct status. Those fields remain unspecified rather than inferred.

• 2008

  Supreme Court declines appeal

  [1]Expanded accessen.wikipedia.org

  The Supreme Court declined to hear the Alliance's appeal, leaving the appellate ruling in effect.

• 2007

  Federal appeals court rules against the Alliance

  [1]Expanded accessen.wikipedia.org

  On August 7, the U.S. Court of Appeals for the District of Columbia Circuit ruled 8–2 against the Alliance in Abigail Alliance v. von Eschenbach and reversed an earlier decision.

• 2001

  Organization established

  [1]Expanded accessen.wikipedia.org

  Frank Burroughs established the Abigail Alliance in November 2001 in memory of his daughter, with a mission centered on broader access to developmental drugs for people with terminal illnesses.

A patient-rights advocacy organization positioned around earlier and broader access to investigational medicines for people with serious or terminal illnesses, particularly when approved treatment options are unavailable or inadequate.

Product categories. Patient advocacy · Public-policy advocacy concerning investigational drugs · Legal and public education support related to expanded access

• 2001Expanded access to developmental drugs

  United States

  The Alliance's central advocacy campaign sought broader availability of investigational medicines for terminally ill patients who lacked satisfactory approved treatment options.

  Outcome. The campaign helped keep pre-approval access in public debate, but did not establish a general legal right to obtain unapproved drugs.

  Source
• 2001Abigail Alliance v. von Eschenbach

  United States

  Through litigation supported by the Washington Legal Foundation, the organization sought constitutional recognition of terminally ill patients' right to access certain investigational drugs.

  Outcome. The D.C. Circuit rejected the claim in 2007, and the Supreme Court declined review in 2008.

  Source

• 2007

  Pursuit of appellate review in the expanded-access caseOther

  Background

  The Alliance's legal campaign argued that terminally ill patients should be able to obtain potentially beneficial investigational medicines before regulatory approval.

  Action taken

  The organization continued its appeal after the D.C. Circuit reversed an earlier favorable ruling and ruled against its claimed constitutional right.

  Aftermath

  The Supreme Court declined review in 2008, leaving the appellate decision intact.

  Source

1. 1Expanded accessen.wikipedia.org
2. 2Abigail Alliance for Better Access to Developmental Drugsen.wikipedia.org